IL146519A0 - 5-phenyl-pyrimidine derivatives - Google Patents

5-phenyl-pyrimidine derivatives

Info

Publication number
IL146519A0
IL146519A0 IL14651900A IL14651900A IL146519A0 IL 146519 A0 IL146519 A0 IL 146519A0 IL 14651900 A IL14651900 A IL 14651900A IL 14651900 A IL14651900 A IL 14651900A IL 146519 A0 IL146519 A0 IL 146519A0
Authority
IL
Israel
Prior art keywords
phenyl
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
IL14651900A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL146519A0 publication Critical patent/IL146519A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL14651900A 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives IL146519A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31
PCT/EP2000/004702 WO2000073278A2 (en) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
IL146519A0 true IL146519A0 (en) 2002-07-25

Family

ID=8238270

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14651900A IL146519A0 (en) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives
IL146519A IL146519A (en) 1999-05-31 2001-11-15 Derivatives of 5-phenyl-pyrimidine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146519A IL146519A (en) 1999-05-31 2001-11-15 Derivatives of 5-phenyl-pyrimidine

Country Status (36)

Country Link
US (1) US6756380B1 (xx)
EP (1) EP1187814B1 (xx)
JP (1) JP3590591B2 (xx)
KR (1) KR100478369B1 (xx)
CN (1) CN1187338C (xx)
AR (1) AR024145A1 (xx)
AT (1) ATE273962T1 (xx)
AU (1) AU769265B2 (xx)
BR (1) BR0011097A (xx)
CA (1) CA2375670C (xx)
CO (1) CO5170529A1 (xx)
CZ (1) CZ20014273A3 (xx)
DE (1) DE60013127T2 (xx)
DK (1) DK1187814T3 (xx)
ES (1) ES2225144T3 (xx)
GC (1) GC0000338A (xx)
HK (1) HK1046411B (xx)
HR (1) HRP20010867A2 (xx)
HU (1) HU225016B1 (xx)
IL (2) IL146519A0 (xx)
JO (1) JO2308B1 (xx)
MA (1) MA26794A1 (xx)
MX (1) MXPA01011704A (xx)
MY (1) MY136258A (xx)
NO (1) NO321334B1 (xx)
NZ (1) NZ515408A (xx)
PE (1) PE20010203A1 (xx)
PL (1) PL353492A1 (xx)
PT (1) PT1187814E (xx)
RU (1) RU2244710C2 (xx)
SI (1) SI1187814T1 (xx)
TR (1) TR200103460T2 (xx)
TW (1) TWI263638B (xx)
WO (1) WO2000073278A2 (xx)
YU (1) YU85001A (xx)
ZA (1) ZA200109496B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
DE60113104D1 (de) * 2000-06-13 2005-10-06 Basf Ag 5 phenyl substituierte 2-(cyanoamino)-pyrimidine als fungizide
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
CN1665506A (zh) 2002-07-02 2005-09-07 霍夫曼-拉罗奇有限公司 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
CA2545259A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
MX2017009843A (es) * 2015-01-30 2017-11-02 Basf Se Fenilpirimidinas herbicidas.
CN109475123B (zh) 2016-07-20 2021-07-09 巴斯夫欧洲公司 包含苯基嘧啶类的除草组合物
CN109476630A (zh) * 2016-07-25 2019-03-15 巴斯夫欧洲公司 除草的嘧啶化合物
CA3030084A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
AU2017302983A1 (en) 2016-07-26 2019-01-03 Basf Se Herbicidal pyrimidine compounds
WO2018019765A1 (en) 2016-07-27 2018-02-01 Basf Se Herbicidal pyrimidine compounds
CA3030217A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyrimidine compounds
US20200146289A1 (en) 2017-06-14 2020-05-14 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2020058062A1 (de) * 2018-09-19 2020-03-26 Bayer Aktiengesellschaft Herbizid wirksame substituierte phenylpyrimidinhydrazide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
DE69434991T2 (de) 1993-12-29 2008-03-06 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel
EP0850228A1 (en) 1995-09-01 1998-07-01 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions

Also Published As

Publication number Publication date
GC0000338A (en) 2007-03-31
CA2375670A1 (en) 2000-12-07
MA26794A1 (fr) 2004-12-20
RU2244710C2 (ru) 2005-01-20
AU769265B2 (en) 2004-01-22
HK1046411A1 (en) 2003-01-10
CO5170529A1 (es) 2002-06-27
JP2003500477A (ja) 2003-01-07
MXPA01011704A (es) 2002-05-14
AR024145A1 (es) 2002-09-04
US6756380B1 (en) 2004-06-29
IL146519A (en) 2006-12-10
KR100478369B1 (ko) 2005-03-24
HUP0201527A3 (en) 2005-01-28
ZA200109496B (en) 2003-02-17
WO2000073278A3 (en) 2001-07-05
NO321334B1 (no) 2006-04-24
DE60013127D1 (de) 2004-09-23
DK1187814T3 (da) 2004-12-20
MY136258A (en) 2008-09-30
CN1187338C (zh) 2005-02-02
PL353492A1 (en) 2003-11-17
NO20015701L (no) 2001-11-22
HK1046411B (zh) 2005-05-27
TR200103460T2 (tr) 2002-05-21
HRP20010867A2 (en) 2003-04-30
NZ515408A (en) 2004-02-27
JP3590591B2 (ja) 2004-11-17
KR20020003399A (ko) 2002-01-12
BR0011097A (pt) 2002-03-19
CZ20014273A3 (cs) 2002-05-15
SI1187814T1 (en) 2004-12-31
CN1353696A (zh) 2002-06-12
JO2308B1 (en) 2005-09-12
TWI263638B (en) 2006-10-11
HU225016B1 (en) 2006-05-29
CA2375670C (en) 2009-09-29
AU5070800A (en) 2000-12-18
WO2000073278A2 (en) 2000-12-07
HUP0201527A2 (en) 2002-08-28
ATE273962T1 (de) 2004-09-15
EP1187814B1 (en) 2004-08-18
ES2225144T3 (es) 2005-03-16
EP1187814A2 (en) 2002-03-20
PT1187814E (pt) 2004-10-29
DE60013127T2 (de) 2005-09-08
NO20015701D0 (no) 2001-11-22
YU85001A (sh) 2004-09-03
PE20010203A1 (es) 2001-02-15

Similar Documents

Publication Publication Date Title
EG23817A (en) 4-Phenyl-pyridine derivatives
HUP0201535A2 (en) 5-cyano-2-aminopyrimidine derivatives
IL148167A0 (en) Amino-triazolopyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
IL145739A0 (en) 13-methyl-erythromycin derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
IL148837A0 (en) Isoxazolecarboxamide derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GB9925880D0 (en) B-Carboline derivatives
IL150132A0 (en) Cyclopenteneone derivatives
IL147636A0 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
IL145949A0 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PL351407A1 (en) Thio-oxindole derivatives
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
IL146282A0 (en) Thio-oxindole derivatives
HK1043987A1 (zh) 硫-羥吲衍生物
SI1178984T1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
SI1200445T1 (en) Thienopyranecarboxamide derivatives
SI1226131T1 (en) Isoxazolecarboxamide derivatives

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees